EUVIMEDEUVIMED entdecken
Crossref

Altered HLA‐A2‐restricted TP53 epitope induces specific CTL cytotoxicity against hepatocellular carcinoma

Chunmei Ye, Shengzhe Lin, Jingwen Hong, Fang Liu, Guoxiang Guo, Shuping Chen, Zhifeng Zhou, Wansong Lin, Jieyu Li, Yunbin Ye

European Journal of Immunology · 2023

DOI: 10.1002/eji.202250054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Immunology, 2023. Verfasst von Chunmei Ye und 9 weiteren Autor:innen. Beteiligte Einrichtung: The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Fujian Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High‐frequency mutation of the TP53 tumor suppressor gene is observed in multiple human cancers, which promotes cancer progression. However, the mutated gene‐encoded protein may serve as a tumor antigen to elicit tumor‐specific immune responses. In this study, we detected widespread expression of shared TP53‐Y220C neoantigen in hepatocellular carcinoma with low affinity and low stability of binding to HLA‐A0201 molecules. We substituted the amino acid sequences VVPCEPPEV with VLPCEPPEV in the TP53‐Y220C neoantigen to yield a TP53‐Y220C (L2) neoantigen. This altered neoantigen was found to increase affinity and stability and induce more cytotoxic T lymphocytes (CTLs), indicating improvements in immunogenicity. In vitro assays showed the cytotoxicity of CTLs stimulated by both TP53‐Y220C and TP53‐Y220C (L2) neoantigens against multiple HLA‐A0201‐positive cancer cells expressing TP53‐Y220C neoantigens; however, the TP53‐Y220C (L2) neoantigen showed higher cytotoxicity than the TP53‐Y220C neoantigen against cancer cells. More importantly, in vivo assays demonstrated greater inhibition of hepatocellular carcinoma cell proliferation by TP53‐Y220C (L2) neoantigen‐specific CTLs relative to TP53‐Y220C neoantigen in zebrafish and nonobese diabetic/severe combined immune deficiency mouse models. The results of this study demonstrate enhanced immunogenicity of the shared TP53‐Y220C (L2) neoantigen, which has the potential as dendritic cells or peptide vaccines for multiple cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAnimalsMiceHumansT-Lymphocytes, CytotoxicHLA-A2 AntigenEpitopesZebrafishAntigens, NeoplasmCytotoxicity, ImmunologicTumor Suppressor Protein p53

Stichwörter der Autor:innen

Hepatocellular carcinomaImmunotherapyShared neoantigenTP53

Substanzen

HLA-A2 AntigenEpitopesAntigens, NeoplasmTP53 protein, humanTumor Suppressor Protein p53

Autor:innen und Institutionen

  • The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
  • Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
  • Laboratory of Immuno-Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou, China.

Förderung

  • Fujian Medical University

Zitieren

APA

Ye, C., Lin, S., Hong, J., Liu, F., Guo, G., Chen, S., Zhou, Z., Lin, W., Li, J., & Ye, Y. (2023). Altered HLA‐A2‐restricted TP53 epitope induces specific CTL cytotoxicity against hepatocellular carcinoma. European Journal of Immunology. https://doi.org/10.1002/eji.202250054

Vancouver

Ye C, Lin S, Hong J, Liu F, Guo G, Chen S, et al. Altered HLA‐A2‐restricted TP53 epitope induces specific CTL cytotoxicity against hepatocellular carcinoma. European Journal of Immunology. 2023. doi:10.1002/eji.202250054

BibTeX
@article{Ye2023,
  author = {Ye, Chunmei and Lin, Shengzhe and Hong, Jingwen and Liu, Fang and Guo, Guoxiang and Chen, Shuping and Zhou, Zhifeng and Lin, Wansong and Li, Jieyu and Ye, Yunbin},
  title = {Altered HLA‐A2‐restricted TP53 epitope induces specific CTL cytotoxicity against hepatocellular carcinoma},
  journal = {European Journal of Immunology},
  year = {2023},
  doi = {10.1002/eji.202250054}
}
Kostenlos starten →